Figure 2.
Figure 2. RPS19-silenced cells display reduced erythroid colony formation capacity mimicking DBA cells. (A) Erythroid colonies decrease with RPS19 silencing in CD34+ CB cells. (B) CFU-G/GM colony formation was not significantly decreased in transduced CD34+ CB cells. (C) In transduced CD34+ BM cells the BFU-E colony-forming defect resembles that in CB cells, again, correlating with RPS19 silencing. (D) RPS19 silencing in BM cells also results in a myeloid colony-forming defect that is significant in LV-TH-RPS19-C-transduced cells. In 2 experiments with Scr-transduced DBA patient BM cells, these cells show a similar colony-forming defect as healthy LV-TH-RPS19-B-transduced cells. Experiments with LV-TH-RPS19-Scr-transduced DBA patient CD34+ BM cells were repeated twice. For all panels, the means ± SEMs for 5 independent experiments are shown. *P < .05, **P < .01 compared with LV-TH-RPS19-Scr-transduced cells.

RPS19-silenced cells display reduced erythroid colony formation capacity mimicking DBA cells. (A) Erythroid colonies decrease with RPS19 silencing in CD34+ CB cells. (B) CFU-G/GM colony formation was not significantly decreased in transduced CD34+ CB cells. (C) In transduced CD34+ BM cells the BFU-E colony-forming defect resembles that in CB cells, again, correlating with RPS19 silencing. (D) RPS19 silencing in BM cells also results in a myeloid colony-forming defect that is significant in LV-TH-RPS19-C-transduced cells. In 2 experiments with Scr-transduced DBA patient BM cells, these cells show a similar colony-forming defect as healthy LV-TH-RPS19-B-transduced cells. Experiments with LV-TH-RPS19-Scr-transduced DBA patient CD34+ BM cells were repeated twice. For all panels, the means ± SEMs for 5 independent experiments are shown. *P < .05, **P < .01 compared with LV-TH-RPS19-Scr-transduced cells.

Close Modal

or Create an Account

Close Modal
Close Modal